ALXO - alxoncology.com Price to Earnings Adjusted for Growth Rate

The PEG ratio chart allows for an assessment of the potential of ALX Oncology Holdings (ALXO), considering the colossal pricing power resulting from inelastic demand for the unique evorpacept. The business focuses on the selective blocking of CD47 to protect erythrocytes, while a patent moat provides an advantage in combination therapy. The current 0.00 indicator determines the magnitude of the metric, helping to understand how fairly the market prices in the development rates of this innovative project.
Metric breakdowns and analytics for alxoncology.com (ALXO)

ALX Oncology Holdings (ALXO) focus on CD47 blockade creates significant risks due to low drug portfolio diversification. When analyzing the PEG ratio, an investor compares the current P/E multiple with the earnings growth rate. The value of 0.00 reflects the degree of asset overvaluation relative to its expansion. A metric below one signals that the company is undervalued. This allows for an objective assessment of business resilience amid fierce competition within the oncology sector.